Chinese replacement heart valve maker Venus Medtech has announced that it received a $37 million investment from Goldman Sachs.
Venus Medtech already has a transcatheter aortic valve replacement (TAVR), the A-Valve, on the market in the People’s Republic and said a pulmonary valve is in clinical trials.
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
The A-Valve is the only TAVR device that meets China Food & Drug Administration requirements. The Venus P-valve pulmonary replacement has already been implanted in more than 40 patients, and the current goal is to win CE Mark approval. They will reportedly be enrolling patients to accomplish this in the early half of the year.
Venus also brought in money from Qiming Venture Partners, Sequoia Capital China and Dinova Venture Capital.
Photo: Flickr user Pictures of Money